Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models

Y Yaozhong Liu (Frankel Cardiovascular Center, Department of Internal Medicine (Y.L., H.W., Ying Zhao, Y.C., Y.D., Yang Zhao, X.W., G.Z., C.X., H. Liu, I.S., L.C., J.Z., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor.) H Huilun Wang (Frankel Cardiovascular Center, Department of Internal Medicine (Y.L., H.W., Ying Zhao, Y.C., Y.D., Yang Zhao, X.W., G.Z., C.X., H. Liu, I.S., L.C., J.Z., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor.) M Minzhi Yu (Department of Pharmacology, University of Michigan, Ann Arbor (M.Y., A.S.).) L Lei Cai (New Cornerstone Science Laboratory, Beijing Advanced Innovation Center for Integrated Circuits, School of Integrated Circuits, Peking University, Beijing, China.) Y Ying Zhao (Division of Biobased Chemicals) Y Yalun Cheng (Frankel Cardiovascular Center, Department of Internal Medicine (Y.L., H.W., Ying Zhao, Y.C., Y.D., Yang Zhao, X.W., G.Z., C.X., H. Liu, I.S., L.C., J.Z., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor.) Y Yongjie Deng Y Yang Zhao H Haocheng Lu X Xiaokang Wu (Smidt Heart Institute, Department of Cardiology, Cedars-Sinai Medical Center and Health Sciences University) G Guizhen Zhao (University of Houston, Houston, Texas, United States) C Chao Xue H Hongyu Liu (School of Materials and Energy) I Ida Surakka (Department of Internal Medicine, Division of Cardiology (T.R., I.S., C.J.W., B.Y.)) A Anna Schwendeman (Department of Pharmaceutical Sciences, University of Michigan) H Hong S. Lu A Alan Daugherty L Lin Chang J Jifeng Zhang R Ryan E. Temel Y Y. Eugene Chen Y Yanhong Guo

Abstract

BACKGROUND: Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease with no effective pharmacological treatments. The causal role of triglycerides (TGs) in AAA development remains unclear and controversial. METHODS: Mendelian randomization was applied to assess causal relationships between lipoproteins, circulating proteins, metabolites, and the risk of AAA. To test the hypothesis that elevated plasma TG levels accelerate AAA development, we used Lpl -deficient, Apoa5 -deficient, and human APOC3 transgenic mice, which display varying degrees of hypertriglyceridemia. Mechanistic studies were performed using RNA sequencing and Western blot analysis of palmitate-treated vascular smooth muscle cells and validated in vivo by local overexpression of key mediator in the suprarenal abdominal aorta. Antisense oligonucleotides targeting Angptl3 were administered to reduce TG levels and assess therapeutic potential in human APOC3 transgenic and Apoe -deficient mice. RESULTS: Mendelian randomization analyses integrating genetic, proteomic, and metabolomic data identified causal relationships between elevated TG-rich lipoproteins, TG metabolism–related proteins/metabolites, and AAA risk. In the angiotensin II infusion AAA model, most Lpl -deficient mice with severely elevated TG concentrations died of aortic rupture. Similarly, Apoa5 -deficient mice with moderately elevated TG levels developed accelerated AAA, and human APOC3 transgenic mice with dramatically elevated TG levels exhibited aortic dissection and rupture. Mechanistically, elevated TG and palmitate inhibited lysyl oxidase (LOX) maturation and reduced LOX activity. Locally overexpressing lysyl oxidase eliminated the proaneurysmal effect of hypertriglyceridemia in human APOC3 transgenic mice. Moreover, an Angptl3 -targeting antisense oligonucleotide profoundly attenuated AAA progression in both human APOC3 transgenic and Apoe -deficient mice. CONCLUSIONS: These findings identify hypertriglyceridemia as a key contributor to AAA pathogenesis and suggest that targeting TG-rich lipoproteins may be a promising therapeutic strategy for AAA.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue 12
Published September 23, 2025
Pages 862-881
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (22)

Y

Yaozhong Liu

Frankel Cardiovascular Center, Department of Internal Medicine (Y.L., H.W., Ying Zhao, Y.C., Y.D., Yang Zhao, X.W., G.Z., C.X., H. Liu, I.S., L.C., J.Z., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor.

H

Huilun Wang

Frankel Cardiovascular Center, Department of Internal Medicine (Y.L., H.W., Ying Zhao, Y.C., Y.D., Yang Zhao, X.W., G.Z., C.X., H. Liu, I.S., L.C., J.Z., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor.

M

Minzhi Yu

Department of Pharmacology, University of Michigan, Ann Arbor (M.Y., A.S.).

L

Lei Cai

New Cornerstone Science Laboratory, Beijing Advanced Innovation Center for Integrated Circuits, School of Integrated Circuits, Peking University, Beijing, China.

Y

Ying Zhao

Division of Biobased Chemicals

Y

Yalun Cheng

Frankel Cardiovascular Center, Department of Internal Medicine (Y.L., H.W., Ying Zhao, Y.C., Y.D., Yang Zhao, X.W., G.Z., C.X., H. Liu, I.S., L.C., J.Z., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor.

Y

Yongjie Deng

Y

Yang Zhao

H

Haocheng Lu

X

Xiaokang Wu

Smidt Heart Institute, Department of Cardiology, Cedars-Sinai Medical Center and Health Sciences University

G

Guizhen Zhao

University of Houston, Houston, Texas, United States

C

Chao Xue

H

Hongyu Liu

School of Materials and Energy

I

Ida Surakka

Department of Internal Medicine, Division of Cardiology (T.R., I.S., C.J.W., B.Y.)

A

Anna Schwendeman

Department of Pharmaceutical Sciences, University of Michigan

H

Hong S. Lu

A

Alan Daugherty

L

Lin Chang

J

Jifeng Zhang

R

Ryan E. Temel

Y

Y. Eugene Chen

Y

Yanhong Guo